protein-degraders
(2)
Fathom Therapeutics
Fathom Therapeutics (formerly Atommap) is a New York and Boston based biotech building Microcosmos, a drug-design engine that fuses quantum chemistry and AI to simulate how proteins actually move inside living cells. By modeling motion instead of static snapshots - reportedly up to 10,000x faster than conventional simulation - the company hunts for the fleeting binding pockets that make 'undruggable' targets druggable, then designs small molecules, degraders, and molecular glues against them. In April 2026 it raised a $47M oversubscribed Series A led by Sutter Hill Ventures.
Ganesh Kaundinya
Ganesh Kaundinya is President and CEO of GlycoEra, a Swiss-US biotech building extracellular protein degraders to treat autoimmune disease. An MIT-trained chemical engineer, he co-founded Momenta Pharmaceuticals and helped grow it from a sugar-sequencing concept into a public company with FDA-approved products, later acquired by Johnson & Johnson for $6.5 billion. At GlycoEra he raised an oversubscribed $130 million Series B in 2025 to push a precision IgG4 degrader toward the clinic.